Table 2.
The introduction of various MTKIs nanoparticles.
| MTKIs | Nanoparticles | Carrier type | Average particle size (nm) (±S.D.) | Zeta potential (mV) (±S.D.) | PDI | Entrapment efficiency (EE%) | Drug loading (DL%) | Ref. |
|---|---|---|---|---|---|---|---|---|
| Sorafenib | Sorafenib-LNS | Liposomes | 164.5(±4.5) | −11.0(±0.28) | 0.202(±0.015) | – | 10.55(±0.16) | [62] |
| Sorafenib | HA/SF | Liposomes | 130.57(±14.06) | −18.1(±1.1) | 0.261(±0.004) | – | 6.8(±0.1) | [63] |
| Sorafenib | Resomer®RG 752H | PLGA | 231.3(±30.1) | −22.2(±1.8) | 0.19(±0.04) | 76.6(±2.7) | 11.2(±0.1) | [64] |
| Sorafenib | SRF@Hb-Ce6 | Hemoglobin | 175 | −14.43 | – | 70% | – | [50] |
| Sorafenib | TPTN | Polymer | 181.4(±3.4) | +14.95(±0.60) | 0.236 | 95.02(±1.47) | 2.38(±0.04) | [65] |
| Sorafenib | MMSNs@SO | MSNs | 102.6(±3.06) | −25.43 | 0.119(±0.01) | 5.36(±0.64) | 2.68(±0.32) | [66] |
| Sorafenib | SO@MSN-CS-LA | MSNs | 210.9(±2.8) | +7.7 (±2.6) | 0.258(±0.022) | 57.4(±2.1) | 21.3(±0.9) | [67] |
| Sorafenib | SO/siVEGF@MSN-LA | MSNs | 148.5(±3.5) | +8.3(±3.5) | 0.153(±0.072) | 55.3(±2.9) | 55.3(±2.9) | [68] |
| Sorafenib | ADOPSor NPs | PLGA | 175.25 ± 1.82 | +19 | 0.148 ± 0.004 | 85% | – | [69] |
| Sorafenib | SCN | Polymer | 84.97(±6.03) | – | 0.176(±0.034) | 98.16(±0.23) | 6.54(±0.01) | [70] |
| Sorafenib | NAcGal-DOX/SOR LNPs | Lipid nanoparticles | 121.2(±3.5) | −37.4(±3.6) | 0.16(±0.03) | 83.2(±3.3) | 4.1(±0.4) | [71] |
| Sorafenib | PBB/sorafenib | Copolymer | 240(±7.7) | −28.9(±5.7) | 0.30(±0.07) | – | 3.8(±0.48) | [72] |
| Sorafenib | mPEG-PDLLA | Polymeric | 127.3(±2.0) | −3.35(±0.42) | – | 95(±3.2) | 6.5(±0.2) | [73] |
| Sorafenib | GAL-SSLN | Solid lipid nanoparticles | 111.0(±6.99) | −19.8(±1.11) | 0.354 (±0.024) | 95(±1.8) | – | [74] |
| Sorafenib | DOX + SOR/iRGDNPs | Lipid-polymer | 126.3(±16.4) | −21.4(±4.6) | 0.105(±0.016) | 70.8(±2.8) | 3.6(±0.05) | [75] |
| Sorafenib | LCC-DOX/miR-375 | Lipid-coated calcium carbonate | 100.7(±12.1) | +40.37(±3.38) | 0.116 (±0.03) | – | 35.2(±8.7) | [76] |
| Sorafenib | NP-TPGS-SFB | Polymeric | 118.3(±5.1) | +3.3(±0.4) | 0.15 | 86.5 | 15.5 | [77] |
| Sorafenib | Gal-SLPs | Polyplexes | 95.6 ± 5.2 | −5.6 ± 0.8 | – | 74.5 | 3.6 | [78] |
| Sorafenib | LD-SDN | Lipid-nanoparticles | 126.5 (±1.33) | −25 | 0.135 | 94.5 (±1.62) | 13.5(±0.85) | [79] |
| Sorafenib | GSI-Lip | Liposomes | 100–150 | −10-0 | – | 92.44 (±1.60) | 0.1–0.2 | [80] |
| Sunitinib | Lip-IR780-Sunitinib | Liposomes | 150 | – | – | 90.12(±0.31) | – | [29] |
| Sunitinib | SU-MNC | Micelle | 167.4(±2.4) | +5.4(±1.3) | 0.19(±0.007) | 77.1(±2.5) | 12.9(±0.3) | [27] |
| Sunitinib | SU-PM | PEG-PLA | 125.9(±4.2) | +7.7(±0.8) | 0.20(±0.02) | 82.7(±4.6) | 13.7(±0.6) | [27] |
| Sunitinib | BSA-SPIOs | BSA | 75.6(±4.6) | −32.1 | – | 99.8(±3.2) | 7.0(±0.2) | [43] |
| Sunitinib | FA-Pt@Uio-66 | MOFs | – | ‒6.33 ± 0.45 | – | 75.67 ± 5.57 | 2.52 ± 0.31 | [81] |
| Afatinib | PSL | Liposomes | 46–57 | +48.4 | ＜0.2 | 52% | – | [82] |
| Afatinib | AFT-PLN@MAp | MSN | 225 | −5 | – | – | 15 | [83] |
| Afatinib | A/D-PADP vesicle | Polymeride | 130(±10) | – | – | – | 1.73 | [84] |
| Alectinib | DATAT-MNCA | Polymeride | 122.0 | – | – | 44.9% | – | [85] |
| Osimertinib | OSI + SEL NP | Micelle | 43 | −30 | 0.581 | – | 13 | [86] |
| Osimertinib | CP@NP-cRGD | CaP shell | 123.4(±0.4) | −15.1(±1.4) | <0.25 | 84.6(±2.6) | 0.3(±0.1) | [31] |
| Anlotinib | Anlotinib@IR820 | Micelle | 120 | – | – | – | – | [87] |
| Anlotinib | cRGDyk-AnlotinibRM | Micelle | 30 | −15.6 | – | 98.64% | 8.98 | [88] |
| Erlotinib | DE-NPs | Polymer | 84 | −27.3 | – | – | 2.6 | [89] |
| Erlotinib | EB@QSSQ | Micelle | 112 | – | – | 50.3 | – | [90] |
| Cabozantinib | PMILs | PLGA | 150 | – | 0.15 | 50 | 1 | [91] |
| Dasatinib | Core-shell nanomedicine | PLGA Albumin nano-shell | 80 | – | – | 85 | 1.8 | [92] |
| Lapatinib | T7-LP@LAP | Liposomes | 144(±3) | −4.8(±0.6) | ＜0.3 | 79.1(±5.1) | 5.5(±0.4) | [93] |
| Lenvatinib | Bi/Se NPs | SeNPs | 120 | – | – | – | 10 | [94] |
| Regorafenib | t-LRR | Liposomes | 187 | −28.6 | 0.106 | 93.0 | 0.6 | [95] |
| Imatinib | INPs | PLGA | 250–300 | −10.6 | 0.20 | 89.94 | 2.25 | [96] |